– USA, NC – Bryn Pharma, LLC, a privately-held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointment of Anne Whitaker to its Board of Directors, effective immediately.
“Anne is an accomplished pharmaceutical executive who brings strong cross-functional operational and commercialization expertise to Bryn. She has a demonstrated track record of building successful businesses and leading teams through transformational change to drive business growth. We look forward to her contributions as we work toward the goal of bringing our innovative anaphylaxis treatment to market,” said CEO, Dr. David Dworaczyk.
He added: “Anne’s fresh perspectives, combined with the experience of our board and senior management team, will help usher in a new day for people facing the dire consequences of severe allergic reactions. We are thrilled that she is joining our team.”
About Anne Whitaker
Anne Whitaker brings more than 30 years of extensive leadership and commercialization experience in pharmaceuticals, consumer products, and medical devices to Bryn’s board. She has held senior-level executive leadership roles at Sanofi, GlaxoSmithKline, Bausch Health, and multiple CEO roles for private and public development stage companies. Most recently, Ms. Whitaker served as CEO of Aerami Therapeutics before taking on the Chair of the Board position in November 2020.
“Bryn has made tremendous strides in researching and developing a new approach to treating life-threatening allergic reactions. I’m excited to collaborate with the company’s leadership to chart a course in bringing their investigational technology to market,” said Anne Whitaker.
Ms. Whitaker currently serves as a healthcare-focused advisor for private equity firms and as an independent director on the board of three public companies including Faron Pharmaceuticals (LON: FARN), Caladrius (NASDAQ: CLBS), and Mallinckrodt. She also serves on the board of Curio Digital Therapeutics, Inc., a privately held women’s health-focused digital therapeutics company, and the Board of Trustees for the University of North Alabama. Before joining Aerami, Ms. Whitaker served in multiple C-suite roles for emerging biotechnology and specialty pharmaceutical companies. Before these roles, Ms. Whitaker served as the North America Pharmaceutical Region Head and President for Sanofi from 2011 to 2014, and as SVP from 2008 to 2011 at GlaxoSmithKline, where she ran their Cardiovascular, Metabolic, and Urology business in the US. From 1992 to 2008, Ms. Whitaker held several commercial roles at GSK and a senior-level global role as the SVP, Head of the Organizational and Leadership Development Center of Excellence based in London. Ms. Whitaker started her career in the pharmaceutical industry as a pharmaceutical sales representative for the Upjohn Company after receiving her Bachelor of Science from the University of North Alabama.
About Bryn Pharma
Bryn Pharma is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction.
For more information: https://www.brynpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.